TY  - CONF
AU  - Cottu, P. H.
AU  - Ring, A.
AU  - Marchetti, P.
AU  - Cardoso, F.
AU  - Salvador, J.
AU  - Neven, P.
AU  - Papazisis, K.
AU  - Campone, M.
AU  - Bachelot, T.
AU  - Menon-Singh, L.
AU  - Wu, J.
AU  - Zhou, K.
AU  - De laurentiis, M.
PY  - 2020
DO  - 10.1016/j.annonc.2020.08.435
SN  - 0923-7534
UR  - https://hdl.handle.net/10668/27218
T2  - Annals of oncology
LA  - en
PB  - Elsevier
TI  - Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
TY  - conference output
VL  - 31
ER  -